CoChat

Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class

Bain, Evie K., Bain, Stephen C. · 2021 · Diabetes, Obesity and Metabolism
Cited by 20

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

As of 2021, 9 % of the global population is now affected by type 2 diabetes mellitus (T2DM). In the United Kingdom, 20% of National Health Service in-patients suffer from diabetes as a co-morbidity, while 10% of healthcare expenditure is linked to diabetes. Failed attempts to reduce the diabetes epidemic are due to an inability to halt rising levels of obesity and sedentary lifestyle. This has led to the development of an abundance of therapeutic agents to control hyperglycaemia and in the United States, there are now 12 different classes of glucose-lowering medication. The glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) act in a glucose-dependent manner by enhancing insulin secretion and reducing production of glucagon. GLP-1RAs are peptides that are resistant to dipeptidyl peptidase and provide supra-physiological stimulation of the GLP-1 receptor. They also retard gastric emptying and increase satiety; these effects in tandem lead to weight loss in a substantial proportion of people with T2DM. Exenatide was the first GLP-1RA to be launched and was based on the exendin-4 molecule (isolated from Gila Monster lizard saliva) and is administered by twice-daily subcutaneous injection at meal times due to its short half-life.1 Subsequent GLP-1RAs were longer acting, once daily (OD) preparations (liraglutide and lixisenatide) administered without regard to meals.2, 3 Then in 2011, the European Medicines Agency (EMA) issued authorisation for the first long-acting GLP-1RA, a once-weekly (QW) version of exenatide.4 Currently, the most widely prescribed GLP-1RA is liraglutide, however, the convenience of less frequent dosing has led to an expansion of new prescriptions of the once-weekly GLP-1RAs.5 Unfortunately, exenatide extended-release (ER) is manufactured as microspheres suspended in a vehicle of medium-chain triglycerides, which requires vigorous shaking (>15 seconds) prior to injection.6 Injection-site swelling is also a prevalent issue due to the slow clearance of the co-formulated polymer, which does not resolve itself until several weeks following injection. As a result, exenatide ER is less frequently prescribed and this review will focus on dulaglutide and semaglutide. Dulaglutide was launched in 2014 and is a polypeptide analogue of human GLP-1 covalently linked to the Fc arms of human immunoglobulin G4.7 This structure reduces immunogenicity and is soluble allowing for simple administration of a clear solution. Dulaglutide is administered in four doses (0.75, 1.5, 3.0 and 4.5 mg QW) and the lower two doses have no need for up-titration. More recently, the long-acting GLP-1RA semaglutide was approved (20188). This molecule is 94% homologous with human GLP-1, differing by only two amino acids. There is an 18-carbon fatty di-acid chain attached to amino acid 26 of the molecule that provides strong binding to albumin and facilitates prolonged activity. A benefit of the long-acting GLP-1RA semaglutide is its administration as a clear solution that does not require resuspension. It is initiated at a dose of 0.25 mg QW titrated after 1 month to a maintenance dose of 0.5 mg with the option for further up-titration to 1.0 mg QW. The dulaglutide phase 3 clinical trial programme was known as AWARD (Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes) and assessed its glucose-lowering efficacy versus commonly prescribed second-line therapies. The spectrum of patients with T2DM was broad, extending from treatment-naïve to those needing insulin, and the primary end-point in each trial (AWARD 1-6) was a change in HbA1c.9-14 The primary endpoint was assessed at 26 weeks in AWARD 1 and 3 to 6 and at 52 weeks in AWARD 2 (versus insulin glargine U100). Doses of 0.75 and 1.5 mg QW dulaglutide were assessed and all studies had extended periods of observation (4-78 weeks) allowing for the collection of additional safety data. Both doses of dulaglutide achieved statistically superior glucose-lowering to the following active comparators: metformin; sitagliptin; exenatide and insulin glargine U100. The higher dose of dulaglutide was also non-inferior to liraglutide 1.8 mg OD. From a baseline HbA1c of 59.6 to 69.4 mmol/mol (7.6%-8.5%), the reductions in HbA1c were 7.8 to 17.4 mmol/mol (0.71%-1.59%) for dulaglutide 0.75 mg QW and 8.5 to 17.9 mmol/mol (0.78%-1.64%) for dulaglutide 1.5 mg QW. Post-launch, the dose of dulaglutide for glucose-lowering was increased following the AWARD 11 trial.15 This assessed the efficacy of dulaglutide 3.0 and 4.5 mg QW versus dulaglutide 1.5 mg QW and reported additional glucose-lowering of 1.9 mmol/mol (0.17%) and 3.7 mmol/mol (0.34%), respectively, which were both statistically significant after 36 weeks treatment. Phase 3 clinical trials of semaglutide were named SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 diabetes) and included 8416 people with T2DM (SUSTAIN 1-5).16-20 Semaglutide was assessed in people across the spectrum of T2DM, from t

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14487

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 20

Metadata

Authors
Bain, E. K., & Bain, S. C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2021-09
Volume
23
Issue
S3
Pages
30-39
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3184694631
Cited by
20
References
36
FWCI
2.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class. https://app.cochat.ai/papers/10.1111/dom.14487
The paper
Bain, E. K., & Bain, S. C. (2021). Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14487

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.